The D3 Dopamine Receptor pipeline drugs market research report outlays comprehensive information on the D3 Dopamine Receptor targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the D3 Dopamine Receptor pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Central Nervous System, Gastrointestinal, Oncology, and Respiratory which include the indications Parkinson’s Disease, Schizophrenia, Post Operative Nausea And Vomiting, Gastroparesis, Pheochromocytoma, Glioma, and Idiopathic Pulmonary Fibrosis. It also reviews key players involved in D3 Dopamine Receptor targeted therapeutics development with respective active and dormant or discontinued products.
The D3 Dopamine Receptor pipeline targets constitutes close to 55 molecules. Out of which, approximately 49 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Filing rejected/ Withdrawn, Phase III, Phase II, Phase I, IND/ CTA Filed, Preclinical, and Discovery stages are 3, 2, 8, 12, 12, 1, 8, and 3 respectively. Similarly, the universities portfolio in Phase II, and Preclinical comprises 1, and 5 molecule.
D3 Dopamine Receptor overview
Dopamine receptor D3 (DRD3) is a protein that belongs to the family of G protein-coupled receptors (GPCRs) and plays a crucial role in regulating dopamine signaling in the brain. It is primarily expressed in the limbic system, a neural network associated with emotions, learning, and memory. DRD3 is also found in other brain regions, including the striatum, prefrontal cortex, and hypothalamus.
For a complete picture of D3 Dopamine Receptor’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
